查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1465067

性行为感染传染病诊断市场：按疾病类型、诊断方法、设备类型和最终用户划分 - 全球预测 2024-2030

Sexually Transmitted Disease Diagnostics Market by Disease Type, Diagnostic methods, Device Type, End-Users - Global Forecast 2024-2030
出版日期: | 出版商: 360iResearch | 英文 180 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计2023年性行为感染传染病诊断市场规模为1,065.3亿美元，预估2024年将达1,125.6亿美元，2030年将达1,599.7亿美元，复合年增长率为5.97%。

性行为感染传染病诊断是指用于识别透过性接触传播的感染疾病的一系列医学测试、身体检查和程序。这些诊断对于性行为感染的早期发现、治疗和预防、支持公共卫生工作和个人福祉至关重要。诊断性行为感染传染病 (STD) 的方法有很多种，包括基于实验室的测试，例如核酸增幅检查、培养和酵素免疫分析法(EIA)，以及提供就地检验。全球性传染病盛行率的上升极大地促进了诊断剂的成长。这一增长是由于性行为的变化、缺乏性健康教育和意识以及某些地区的筛检计划不足所造成的。这强调了对有效诊断解决方案的需求，并推动了对性病诊断的需求不断增长。然而，与性病相关的社会耻辱仍然是性病诊断提供者面临的主要挑战。上市公司越来越关注性病预防和控制，将其作为公共卫生的一部分。此外，分子诊断、聚合酵素链锁反应（PCR）检测和免疫检测等医学诊断技术的快速发展显着提高了性病检测的准确性、效率和速度。这些技术进步有利于性病的早期发现和治疗，进一步促进性病诊断的成长。

主要市场统计
基准年[2023] 1065.3亿美元
预测年份 [2024] 1125.6亿美元
预测年份 [2030] 1599.7亿美元
复合年增长率（%） 5.97%

疾病类型次世代定序仪和基于 CRISPR 的诊断方法的进步使得治疗多种性传染病成为可能。

性行为感染传染病 (STD) 诊断研究包括影响性健康的多种疾病。其中包括细菌性阴道炎，这是由阴道细菌失衡引起的，会导致阴道分泌物和不适等症状。念珠菌性阴道炎或酵母菌感染疾病是由念珠菌过度生长引起的，会引起搔痒和发炎。另一方面，透过性接触传播的感染疾病，例如披衣菌感染衣原体和淋病奈瑟菌，通常不会立即引起症状，如果不及时治疗，可能会导致严重的生殖问题。生殖器湿疣是由某些 HPV 菌株引起的，在生殖器部位表现为疣。爱滋病毒/爱滋病严重削弱免疫系统，导致危及生命的感染疾病。一种鲜为人知的细菌，称为生殖霉浆菌，与尿道炎和发炎等疾病有关。梅毒是一种分阶段进展的细菌感染疾病，最初会引起溃疡和皮疹，如果不治疗，会导致内臟器官严重受损。最后，滴虫性阴道炎是由滴虫原生动物引起的，其特征是搔痒和分泌物，但通常可以用抗生素治癒。

最终使用者：临床和医院环境中越来越多地采用性病诊断来解决复杂的性病病例。

性行为感染传染病 (STD) 诊断有多种医疗保健和监测设置，每种设置在 STD 检测、分析和管理中都发挥着重要作用。诊所通常是性病诊断的前线，提供公众可以直接获得的检测服务。诊断实验室专门使用先进技术分析检体以获得准确的结果。医院提供包括性病诊断在内的综合治疗，特别是需要住院治疗的重症、复杂病例。公共卫生机构透过使用诊断资料为公共卫生策略和干预措施提供讯息，对于监测、预防和控制性传染病至关重要。此外，研究机构在开发新的诊断方法和了解性传染病的流行病学方面发挥着重要作用，有助于建立推进公共卫生措施和临床实践所需的科学基础设施。

区域洞察

美洲性行为感染(STD) 的盛行率不断上升，加上健康意识和医疗保健支出的增加，正在推动对诊断解决方案的需求。先进的医疗保健基础设施和尖端诊断技术的高普及有助于提高消费者的期望。最近的努力包括对公共卫生计划进行大量投资，以加强弱势群体的性病诊断。同时，欧洲、中东和非洲正在展示一种积极主动的性病诊断方法，并得到政府和非政府倡议的支持，促进创新诊断解决方案的研究、开发和分销。注重性价比、全面覆盖，实现都市区便捷使用。近年来，亚太地区在教育、意识和减少性传染病耻辱方面的努力逐渐取得进展，导致对诊断服务的需求逐渐增加。此外，由于人们对性病的认识不断提高、性病患病率不断上升以及政府旨在控制这些感染疾病的倡议，亚太地区热衷于发展性病诊断市场。由于中国、印度、日本和澳洲等国家的人口多样化和医疗基础设施多样化，先进技术的采用和对具有成本效益的诊断解决方案不断增长的需求推动了市场动态。

FPNV定位矩阵

FPNV 定位矩阵对于评估性行为感染传染病诊断市场至关重要。我们检视与业务策略和产品满意度相关的关键指标，以对供应商进行全面评估。这种深入的分析使用户能够根据自己的要求做出明智的决策。根据评估，供应商被分为四个成功程度不同的像限：前沿（F）、探路者（P）、利基（N）和重要（V）。

市场占有率分析

市场占有率分析是一种综合工具，可以对性行为感染诊断市场供应商的现状进行深入而深入的研究。全面比较和分析供应商在整体收益、基本客群和其他关键指标方面的贡献，以便更好地了解公司的绩效及其在争夺市场占有率时面临的挑战。此外，该分析还提供了对该行业竞争特征的宝贵见解，包括在研究基准年观察到的累积、分散主导地位和合併特征等因素。这种详细程度的提高使供应商能够做出更明智的决策并制定有效的策略，从而在市场上获得竞争优势。

本报告对以下几个方面提供了宝贵的见解：

1. 市场渗透率：提供有关主要企业所服务的市场的全面资讯。

2. 市场开拓：我们深入研究利润丰厚的新兴市场，并分析其在成熟细分市场的渗透率。

3. 市场多元化：提供有关新产品发布、开拓地区、最新发展和投资的详细资讯。

4. 竞争评估和情报：对主要企业的市场占有率、策略、产品、认证、监管状况、专利状况和製造能力进行全面评估。

5. 产品开发与创新：提供对未来技术、研发活动和突破性产品开发的见解。

本报告解决了以下关键问题：

1.性行为感染传染病诊断市场的市场规模和预测是多少？

2.在性行为感染诊断市场的预测期间内，有哪些产品、细分市场、应用和领域需要考虑投资？

3.性行为感染传染病诊断市场的技术趋势和法规结构是什么？

4.性行为感染诊断市场主要厂商的市场占有率为何？

5.进入性行为感染诊断市场的合适型态和策略手段是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 全球性传染病的日益普及增加了对有效诊断解决方案的需求
      • 在全球范围内增加检测，以减少与性行为感染相关的耻辱
    • 抑制因素
      • 对性行为感染传染病缺乏足够的认知与教育
    • 机会
      • 增加对性行为感染传染病的认识和预防的资金和公共卫生宣传活动
      • 次世代定序和基于 CRISPR 的诊断的创新
    • 任务
      • 关于药物核准和未经治疗的感染疾病引起的併发症的严格政府法规
  • 市场区隔分析
    • 疾病类型：次世代定序和基于 CRISPR 的诊断技术的进步可解决多种 STD
    • 最终用户：在临床和医院环境中更多地采用性行为感染诊断来解决复杂的性行为感染病例
  • 市场扰动分析
  • 波特五力分析
  • 价值炼和关键路径分析
  • 价格分析
  • 技术分析
  • 专利分析
  • 贸易分析
  • 法规结构分析

第六章性行为感染传染病诊断市场：依疾病类型

  • 细菌性阴道炎
  • 念珠菌性阴道炎
  • 披衣菌感染披衣菌/淋病双球菌
  • 尖圭湿疣
  • B型肝炎
  • HIV爱滋病
  • 霉浆菌支原体
  • 梅毒
  • 滴虫病

第七章依诊断方法性行为感染传染病诊断药物市场

  • 抗原检测
  • 分子诊断
  • 血清学检测

第八章按设备类型性行为感染传染病诊断市场

  • 实验装置
  • 照护现场设备

第九章性行为感染传染病诊断市场：依最终用户分类

  • 诊所
  • 诊断实验室
  • 医院
  • 公共卫生机构
  • 调查机构

第十章 南北美洲性行为感染诊断药物市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十一章亚太性行为感染诊断市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十二章 欧洲、中东、非洲性行为感染诊断药物市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十三章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
    • 英国Start-Ups推出具有性行为感染感染测试功能的卫生棉条
    • BioPerfectus 推出新型 PCR套件，用于性行为感染传染病诊断解决方案
    • MyLab 推出性行为感染传染病快速检测
  • 战略分析和建议

第14章竞争产品组合

  • 主要企业简介
  • 主要产品系列
Product Code: MRR-6D54EA0F9447

[180 Pages Report] The Sexually Transmitted Disease Diagnostics Market size was estimated at USD 106.53 billion in 2023 and expected to reach USD 112.56 billion in 2024, at a CAGR 5.97% to reach USD 159.97 billion by 2030.

Sexually transmitted disease diagnostics refers to the range of medical tests, physical examinations, and procedures used to identify infections transmitted through sexual contact. These diagnostics are crucial for the early detection, treatment, and prevention of sexually transmitted diseases, supporting public health efforts and individual well-being. The methodologies for Sexually transmitted disease (STD) diagnostics vary, including laboratory-based tests such as nucleic acid amplification tests, cultures, enzyme immunoassays (EIAs), and point-of-care tests that offer rapid results. The rising prevalence of STDs worldwide is a major contributor to the growth of diagnostics. This increase is attributed to changing sexual behaviors, lack of education and awareness regarding sexual health, and insufficient screening programs in certain regions. The need for effective diagnostic solutions is thus highlighted, prompting an uptick in demand for STD diagnostics. However, the social stigma associated with STDs remains a significant challenge for STD diagnostic providers. Companies are increasingly focusing on STD prevention and control as part of their public health initiatives. Moreover, the rapid progress in medical diagnostic technologies, including molecular diagnostics, Polymerase Chain Reaction (PCR) testing, and immunoassays, has significantly enhanced the accuracy, efficiency, and speed of STD testing. These technological advancements facilitate the early detection and treatment of STDs, further driving the growth of STD diagnostics.

KEY MARKET STATISTICS
Base Year [2023] USD 106.53 billion
Estimated Year [2024] USD 112.56 billion
Forecast Year [2030] USD 159.97 billion
CAGR (%) 5.97%

Disease Type: Advancements in next-generation sequencing and CRISPR-based diagnostics to cater varied STDs

The study of sexually transmitted disease (STD) diagnostics encompasses a broad range of conditions affecting sexual health. These include bacterial vaginosis, a condition stemming from an imbalance of bacteria in the vagina, which leads to symptoms such as discharge and discomfort. Candidal vaginitis or yeast infection arises from an overgrowth of Candida fungi, causing itching and irritation. On the other hand, infections such as Chlamydia trachomatis and Neisseria Gonorrhoeae, transmitted through sexual contact, often show no immediate symptoms and can lead to severe reproductive issues that are left unaddressed. Genital Warts are the result of certain HPV strains, presenting as warts on the genital area. HIV/AIDS severely impairs the immune system, leading to life-threatening infections. The bacterium Mycoplasma genitalium, though lesser known, is linked to conditions such as urethritis and pelvic inflammatory disease. Syphilis, a bacterial infection, progresses through stages, initially causing sores and skin rashes and, without treatment, severe damage to internal organs. Lastly, Trichomoniasis, caused by the Trichomonas vaginalis protozoan, is characterized by itching and discharge but is typically curable with antibiotics.

End-Users: Increasing adoption of STD diagnostics in clinical and hospital settings to cater complicated STD cases

Sexually transmitted disease (STD) diagnostics encompass various healthcare and research settings, each playing an important role in the detection, analysis, and management of STDs. Clinics are often the frontline in STD diagnostics, providing accessible testing services directly to the public. Diagnostic laboratories specialize in the analysis of samples, utilizing advanced technologies to ensure accurate results. Hospitals offer comprehensive care, including STD diagnostics, especially in more severe or complicated cases that require in-patient care. Public health agencies are integral to the surveillance, prevention, and control of STDs, using diagnostic data to inform public health strategies and interventions. Moreover, research institutions are key in developing new diagnostic methods and understanding the epidemiology of STDs, contributing to the scientific foundation necessary for advancing public health measures and clinical practices.

Regional Insights

In the Americas, the growing prevalence of sexually transmitted diseases (STDs), coupled with increased health awareness and healthcare spending, propels demand for diagnostic solutions. Advanced healthcare infrastructure and the high adoption of cutting-edge diagnostic technologies contribute to sophisticated consumer expectations. Recent initiatives include significant investments in public health programs to enhance STD diagnostics among underprivileged populations. At the same time, the EMEA shows a proactive approach towards STD diagnostics, supported by governmental and non-governmental initiatives that facilitate research, development, and distribution of innovative diagnostics solutions. The emphasis is on cost-effectiveness and comprehensive coverage, aiming for urban and rural accessibility. In recent years, the region has witnessed gradual progress with initiatives aimed at education, awareness, and breaking the stigma around STDs, slowly increasing the demand for diagnostic services. Moreover, the Asia-Pacific region is keen on growth in the market for STD diagnostics, driven by increasing awareness, rising prevalence of STDs, and government initiatives aimed at curbing these infections. With a diverse population and varying healthcare infrastructure across countries, including China, India, Japan, and Australia, the market dynamics are characterized by a mix of advanced technological adoption and growing demand for cost-effective diagnostic solutions.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Sexually Transmitted Disease Diagnostics Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Sexually Transmitted Disease Diagnostics Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Sexually Transmitted Disease Diagnostics Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Astra Biotech Gmbh, Becton Dickinson and company, Bio-Rad Laboratories, Inc., bioMerieux SA, Danaher Corporation, Daye Limited, Diasorin S.p.A, F. Hoffmann-La Roche Ltd, Geneproof, Hologic Inc., Jiangsu BioPerfectus Technologies Co., Ltd, Liferiver Bio-Tech Corp., MedMira Inc, Meridian Bioscience Inc., Mylab Discovery Solutions Pvt. Ltd., OraSure Technologies, Inc., Qiagen Inc, Quest Consumer Inc., Sansure Biotech Inc., Seegene Inc., Siemens Healthcare GmbH, and Thermo Fisher Scientific, Inc..

Market Segmentation & Coverage

This research report categorizes the Sexually Transmitted Disease Diagnostics Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Disease Type
    • Bacterial Vaginosis
    • Candidal Vaginitis
    • Chlamydia Trachomatis/ Neisseria Gonorrhoeae
    • Genital Warts
    • Hepatitis B
    • HIV/AIDS
    • Mycoplasma Genitalium
    • Syphilis
    • Trichomoniasis
  • Diagnostic methods
    • Antigen Detection
    • Molecular Diagnostics
    • Serologic Testing
  • Device Type
    • Laboratory Devices
      • Absorbance Microplate Reader
      • Differential Light Scattering Machines
      • Flow Cytometers
      • Lateral Flow Readers
      • Thermal Cyclers - PCR
    • Point of Care Devices
      • Phone Chips (Microfluidics + ICT)
      • Rapid Diagnostic Kits
  • End-Users
    • Clinics
    • Diagnostic Laboratories
    • Hospitals
    • Public Health Agencies
    • Research Institutions
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Sexually Transmitted Disease Diagnostics Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Sexually Transmitted Disease Diagnostics Market?

3. What are the technology trends and regulatory frameworks in the Sexually Transmitted Disease Diagnostics Market?

4. What is the market share of the leading vendors in the Sexually Transmitted Disease Diagnostics Market?

5. Which modes and strategic moves are suitable for entering the Sexually Transmitted Disease Diagnostics Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. The rising prevalence of sexual diseases worldwide and the need for effective diagnostic solutions
      • 5.1.1.2. Increasing implementation of worldwide screening to reduce the stigma associated with STD
    • 5.1.2. Restraints
      • 5.1.2.1. Lack of adequate awareness and education about STDs
    • 5.1.3. Opportunities
      • 5.1.3.1. Increased funding and public health campaigns for STD awareness and prevention
      • 5.1.3.2. Innovations in next-generation sequencing and CRISPR-based diagnostics
    • 5.1.4. Challenges
      • 5.1.4.1. Stringent government regulations for drug approvals and complications arising from untreated infections
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Disease Type: Advancements in next-generation sequencing and CRISPR-based diagnostics to cater varied STDs
    • 5.2.2. End-Users: Increasing adoption of STD diagnostics in clinical and hospital settings to cater complicated STD cases
  • 5.3. Market Disruption Analysis
  • 5.4. Porter's Five Forces Analysis
    • 5.4.1. Threat of New Entrants
    • 5.4.2. Threat of Substitutes
    • 5.4.3. Bargaining Power of Customers
    • 5.4.4. Bargaining Power of Suppliers
    • 5.4.5. Industry Rivalry
  • 5.5. Value Chain & Critical Path Analysis
  • 5.6. Pricing Analysis
  • 5.7. Technology Analysis
  • 5.8. Patent Analysis
  • 5.9. Trade Analysis
  • 5.10. Regulatory Framework Analysis

6. Sexually Transmitted Disease Diagnostics Market, by Disease Type

  • 6.1. Introduction
  • 6.2. Bacterial Vaginosis
  • 6.3. Candidal Vaginitis
  • 6.4. Chlamydia Trachomatis/ Neisseria Gonorrhoeae
  • 6.5. Genital Warts
  • 6.6. Hepatitis B
  • 6.7. HIV/AIDS
  • 6.8. Mycoplasma Genitalium
  • 6.9. Syphilis
  • 6.10. Trichomoniasis

7. Sexually Transmitted Disease Diagnostics Market, by Diagnostic methods

  • 7.1. Introduction
  • 7.2. Antigen Detection
  • 7.3. Molecular Diagnostics
  • 7.4. Serologic Testing

8. Sexually Transmitted Disease Diagnostics Market, by Device Type

  • 8.1. Introduction
  • 8.2. Laboratory Devices
  • 8.3. Point of Care Devices

9. Sexually Transmitted Disease Diagnostics Market, by End-Users

  • 9.1. Introduction
  • 9.2. Clinics
  • 9.3. Diagnostic Laboratories
  • 9.4. Hospitals
  • 9.5. Public Health Agencies
  • 9.6. Research Institutions

10. Americas Sexually Transmitted Disease Diagnostics Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Sexually Transmitted Disease Diagnostics Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Sexually Transmitted Disease Diagnostics Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
    • 13.3.1. British startup launches tampon that offers STI screening
    • 13.3.2. BioPerfectus Launches New PCR Kits for Sexually Transmitted Diseases Diagnostic Solution
    • 13.3.3. Mylab Launches rapid tests for sexually transmitted diseases
  • 13.4. Strategy Analysis & Recommendation

14. Competitive Portfolio

  • 14.1. Key Company Profiles
  • 14.2. Key Product Portfolio

LIST OF FIGURES

  • FIGURE 1. SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET RESEARCH PROCESS
  • FIGURE 2. SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET DYNAMICS
  • FIGURE 7. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2023 VS 2030 (%)
  • FIGURE 8. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC METHODS, 2023 VS 2030 (%)
  • FIGURE 10. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC METHODS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DEVICE TYPE, 2023 VS 2030 (%)
  • FIGURE 12. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DEVICE TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY END-USERS, 2023 VS 2030 (%)
  • FIGURE 14. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY END-USERS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. AMERICAS SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 16. AMERICAS SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. UNITED STATES SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 18. UNITED STATES SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. ASIA-PACIFIC SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 20. ASIA-PACIFIC SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 23. SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 24. SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, 2018-2023 (USD MILLION)
  • TABLE 4. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, 2024-2030 (USD MILLION)
  • TABLE 5. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 6. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 7. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 8. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 9. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY BACTERIAL VAGINOSIS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 10. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY BACTERIAL VAGINOSIS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 11. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY CANDIDAL VAGINITIS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 12. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY CANDIDAL VAGINITIS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 13. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY CHLAMYDIA TRACHOMATIS/ NEISSERIA GONORRHOEAE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 14. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY CHLAMYDIA TRACHOMATIS/ NEISSERIA GONORRHOEAE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 15. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY GENITAL WARTS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 16. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY GENITAL WARTS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 17. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY HEPATITIS B, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 18. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY HEPATITIS B, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 19. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY HIV/AIDS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 20. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY HIV/AIDS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 21. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY MYCOPLASMA GENITALIUM, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 22. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY MYCOPLASMA GENITALIUM, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 23. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY SYPHILIS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 24. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY SYPHILIS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 25. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY TRICHOMONIASIS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 26. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY TRICHOMONIASIS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 27. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC METHODS, 2018-2023 (USD MILLION)
  • TABLE 28. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC METHODS, 2024-2030 (USD MILLION)
  • TABLE 29. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY ANTIGEN DETECTION, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 30. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY ANTIGEN DETECTION, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 31. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 32. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 33. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY SEROLOGIC TESTING, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 34. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY SEROLOGIC TESTING, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 35. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DEVICE TYPE, 2018-2023 (USD MILLION)
  • TABLE 36. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DEVICE TYPE, 2024-2030 (USD MILLION)
  • TABLE 37. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY LABORATORY DEVICES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 38. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY LABORATORY DEVICES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 39. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY LABORATORY DEVICES, 2018-2023 (USD MILLION)
  • TABLE 40. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY LABORATORY DEVICES, 2024-2030 (USD MILLION)
  • TABLE 41. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY ABSORBANCE MICROPLATE READER, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 42. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY ABSORBANCE MICROPLATE READER, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 43. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DIFFERENTIAL LIGHT SCATTERING MACHINES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 44. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DIFFERENTIAL LIGHT SCATTERING MACHINES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 45. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY FLOW CYTOMETERS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 46. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY FLOW CYTOMETERS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 47. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY LATERAL FLOW READERS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 48. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY LATERAL FLOW READERS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 49. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY THERMAL CYCLERS - PCR, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 50. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY THERMAL CYCLERS - PCR, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 51. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY POINT OF CARE DEVICES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 52. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY POINT OF CARE DEVICES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 53. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY POINT OF CARE DEVICES, 2018-2023 (USD MILLION)
  • TABLE 54. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY POINT OF CARE DEVICES, 2024-2030 (USD MILLION)
  • TABLE 55. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY PHONE CHIPS (MICROFLUIDICS + ICT), BY REGION, 2018-2023 (USD MILLION)
  • TABLE 56. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY PHONE CHIPS (MICROFLUIDICS + ICT), BY REGION, 2024-2030 (USD MILLION)
  • TABLE 57. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY RAPID DIAGNOSTIC KITS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 58. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY RAPID DIAGNOSTIC KITS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 59. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 60. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 61. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY CLINICS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 62. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY CLINICS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 63. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 64. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 65. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 66. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 67. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY PUBLIC HEALTH AGENCIES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 68. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY PUBLIC HEALTH AGENCIES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 69. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY RESEARCH INSTITUTIONS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 70. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY RESEARCH INSTITUTIONS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 71. AMERICAS SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 72. AMERICAS SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 73. AMERICAS SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC METHODS, 2018-2023 (USD MILLION)
  • TABLE 74. AMERICAS SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC METHODS, 2024-2030 (USD MILLION)
  • TABLE 75. AMERICAS SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DEVICE TYPE, 2018-2023 (USD MILLION)
  • TABLE 76. AMERICAS SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DEVICE TYPE, 2024-2030 (USD MILLION)
  • TABLE 77. AMERICAS SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY LABORATORY DEVICES, 2018-2023 (USD MILLION)
  • TABLE 78. AMERICAS SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY LABORATORY DEVICES, 2024-2030 (USD MILLION)
  • TABLE 79. AMERICAS SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY POINT OF CARE DEVICES, 2018-2023 (USD MILLION)
  • TABLE 80. AMERICAS SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY POINT OF CARE DEVICES, 2024-2030 (USD MILLION)
  • TABLE 81. AMERICAS SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 82. AMERICAS SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 83. AMERICAS SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 84. AMERICAS SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 85. ARGENTINA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 86. ARGENTINA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 87. ARGENTINA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC METHODS, 2018-2023 (USD MILLION)
  • TABLE 88. ARGENTINA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC METHODS, 2024-2030 (USD MILLION)
  • TABLE 89. ARGENTINA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DEVICE TYPE, 2018-2023 (USD MILLION)
  • TABLE 90. ARGENTINA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DEVICE TYPE, 2024-2030 (USD MILLION)
  • TABLE 91. ARGENTINA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY LABORATORY DEVICES, 2018-2023 (USD MILLION)
  • TABLE 92. ARGENTINA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY LABORATORY DEVICES, 2024-2030 (USD MILLION)
  • TABLE 93. ARGENTINA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY POINT OF CARE DEVICES, 2018-2023 (USD MILLION)
  • TABLE 94. ARGENTINA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY POINT OF CARE DEVICES, 2024-2030 (USD MILLION)
  • TABLE 95. ARGENTINA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 96. ARGENTINA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 97. BRAZIL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 98. BRAZIL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 99. BRAZIL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC METHODS, 2018-2023 (USD MILLION)
  • TABLE 100. BRAZIL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC METHODS, 2024-2030 (USD MILLION)
  • TABLE 101. BRAZIL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DEVICE TYPE, 2018-2023 (USD MILLION)
  • TABLE 102. BRAZIL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DEVICE TYPE, 2024-2030 (USD MILLION)
  • TABLE 103. BRAZIL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY LABORATORY DEVICES, 2018-2023 (USD MILLION)
  • TABLE 104. BRAZIL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY LABORATORY DEVICES, 2024-2030 (USD MILLION)
  • TABLE 105. BRAZIL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY POINT OF CARE DEVICES, 2018-2023 (USD MILLION)
  • TABLE 106. BRAZIL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY POINT OF CARE DEVICES, 2024-2030 (USD MILLION)
  • TABLE 107. BRAZIL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 108. BRAZIL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 109. CANADA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 110. CANADA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 111. CANADA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC METHODS, 2018-2023 (USD MILLION)
  • TABLE 112. CANADA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC METHODS, 2024-2030 (USD MILLION)
  • TABLE 113. CANADA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DEVICE TYPE, 2018-2023 (USD MILLION)
  • TABLE 114. CANADA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DEVICE TYPE, 2024-2030 (USD MILLION)
  • TABLE 115. CANADA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY LABORATORY DEVICES, 2018-2023 (USD MILLION)
  • TABLE 116. CANADA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY LABORATORY DEVICES, 2024-2030 (USD MILLION)
  • TABLE 117. CANADA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY POINT OF CARE DEVICES, 2018-2023 (USD MILLION)
  • TABLE 118. CANADA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY POINT OF CARE DEVICES, 2024-2030 (USD MILLION)
  • TABLE 119. CANADA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 120. CANADA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 121. MEXICO SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 122. MEXICO SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 123. MEXICO SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC METHODS, 2018-2023 (USD MILLION)
  • TABLE 124. MEXICO SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC METHODS, 2024-2030 (USD MILLION)
  • TABLE 125. MEXICO SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DEVICE TYPE, 2018-2023 (USD MILLION)
  • TABLE 126. MEXICO SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DEVICE TYPE, 2024-2030 (USD MILLION)
  • TABLE 127. MEXICO SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY LABORATORY DEVICES, 2018-2023 (USD MILLION)
  • TABLE 128. MEXICO SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY LABORATORY DEVICES, 2024-2030 (USD MILLION)
  • TABLE 129. MEXICO SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY POINT OF CARE DEVICES, 2018-2023 (USD MILLION)
  • TABLE 130. MEXICO SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY POINT OF CARE DEVICES, 2024-2030 (USD MILLION)
  • TABLE 131. MEXICO SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 132. MEXICO SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 133. UNITED STATES SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 134. UNITED STATES SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 135. UNITED STATES SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC METHODS, 2018-2023 (USD MILLION)
  • TABLE 136. UNITED STATES SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC METHODS, 2024-2030 (USD MILLION)
  • TABLE 137. UNITED STATES SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DEVICE TYPE, 2018-2023 (USD MILLION)
  • TABLE 138. UNITED STATES SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DEVICE TYPE, 2024-2030 (USD MILLION)
  • TABLE 139. UNITED STATES SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY LABORATORY DEVICES, 2018-2023 (USD MILLION)
  • TABLE 140. UNITED STATES SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY LABORATORY DEVICES, 2024-2030 (USD MILLION)
  • TABLE 141. UNITED STATES SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY POINT OF CARE DEVICES, 2018-2023 (USD MILLION)
  • TABLE 142. UNITED STATES SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY POINT OF CARE DEVICES, 2024-2030 (USD MILLION)
  • TABLE 143. UNITED STATES SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 144. UNITED STATES SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 145. UNITED STATES SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
  • TABLE 146. UNITED STATES SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
  • TABLE 147. ASIA-PACIFIC SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 148. ASIA-PACIFIC SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 149. ASIA-PACIFIC SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC METHODS, 2018-2023 (USD MILLION)
  • TABLE 150. ASIA-PACIFIC SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC METHODS, 2024-2030 (USD MILLION)
  • TABLE 151. ASIA-PACIFIC SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DEVICE TYPE, 2018-2023 (USD MILLION)
  • TABLE 152. ASIA-PACIFIC SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DEVICE TYPE, 2024-2030 (USD MILLION)
  • TABLE 153. ASIA-PACIFIC SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY LABORATORY DEVICES, 2018-2023 (USD MILLION)
  • TABLE 154. ASIA-PACIFIC SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY LABORATORY DEVICES, 2024-2030 (USD MILLION)
  • TABLE 155. ASIA-PACIFIC SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY POINT OF CARE DEVICES, 2018-2023 (USD MILLION)
  • TABLE 156. ASIA-PACIFIC SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY POINT OF CARE DEVICES, 2024-2030 (USD MILLION)
  • TABLE 157. ASIA-PACIFIC SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 158. ASIA-PACIFIC SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 159. ASIA-PACIFIC SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 160. ASIA-PACIFIC SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 161. AUSTRALIA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 162. AUSTRALIA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 163. AUSTRALIA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC METHODS, 2018-2023 (USD MILLION)
  • TABLE 164. AUSTRALIA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC METHODS, 2024-2030 (USD MILLION)
  • TABLE 165. AUSTRALIA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DEVICE TYPE, 2018-2023 (USD MILLION)
  • TABLE 166. AUSTRALIA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DEVICE TYPE, 2024-2030 (USD MILLION)
  • TABLE 167. AUSTRALIA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY LABORATORY DEVICES, 2018-2023 (USD MILLION)
  • TABLE 168. AUSTRALIA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY LABORATORY DEVICES, 2024-2030 (USD MILLION)
  • TABLE 169. AUSTRALIA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY POINT OF CARE DEVICES, 2018-2023 (USD MILLION)
  • TABLE 170. AUSTRALIA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY POINT OF CARE DEVICES, 2024-2030 (USD MILLION)
  • TABLE 171. AUSTRALIA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 172. AUSTRALIA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 173. CHINA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 174. CHINA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 175. CHINA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC METHODS, 2018-2023 (USD MILLION)
  • TABLE 176. CHINA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC METHODS, 2024-2030 (USD MILLION)
  • TABLE 177. CHINA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DEVICE TYPE, 2018-2023 (USD MILLION)
  • TABLE 178. CHINA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DEVICE TYPE, 2024-2030 (USD MILLION)
  • TABLE 179. CHINA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY LABORATORY DEVICES, 2018-2023 (USD MILLION)
  • TABLE 180. CHINA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY LABORATORY DEVICES, 2024-2030 (USD MILLION)
  • TABLE 181. CHINA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY POINT OF CARE DEVICES, 2018-2023 (USD MILLION)
  • TABLE 182. CHINA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY POINT OF CARE DEVICES, 2024-2030 (USD MILLION)
  • TABLE 183. CHINA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 184. CHINA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 185. INDIA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 186. INDIA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 187. INDIA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC METHODS, 2018-2023 (USD MILLION)
  • TABLE 188. INDIA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC METHODS, 2024-2030 (USD MILLION)
  • TABLE 189. INDIA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DEVICE TYPE, 2018-2023 (USD MILLION)
  • TABLE 190. INDIA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DEVICE TYPE, 2024-2030 (USD MILLION)
  • TABLE 191. INDIA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY LABORATORY DEVICES, 2018-2023 (USD MILLION)
  • TABLE 192. INDIA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY LABORATORY DEVICES, 2024-2030 (USD MILLION)
  • TABLE 193. INDIA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY POINT OF CARE DEVICES, 2018-2023 (USD MILLION)
  • TABLE 194. INDIA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY POINT OF CARE DEVICES, 2024-2030 (USD MILLION)
  • TABLE 195. INDIA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 196. INDIA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 197. INDONESIA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 198. INDONESIA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 199. INDONESIA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC METHODS, 2018-2023 (USD MILLION)
  • TABLE 200. INDONESIA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC METHODS, 2024-2030 (USD MILLION)
  • TABLE 201. INDONESIA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DEVICE TYPE, 2018-2023 (USD MILLION)
  • TABLE 202. INDONESIA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DEVICE TYPE, 2024-2030 (USD MILLION)
  • TABLE 203. INDONESIA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY LABORATORY DEVICES, 2018-2023 (USD MILLION)
  • TABLE 204. INDONESIA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY LABORATORY DEVICES, 2024-2030 (USD MILLION)
  • TABLE 205. INDONESIA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY POINT OF CARE DEVICES, 2018-2023 (USD MILLION)
  • TABLE 206. INDONESIA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY POINT OF CARE DEVICES, 2024-2030 (USD MILLION)
  • TABLE 207. INDONESIA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 208. INDONESIA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 209. JAPAN SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 210. JAPAN SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 211. JAPAN SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC METHODS, 2018-2023 (USD MILLION)
  • TABLE 212. JAPAN SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC METHODS, 2024-2030 (USD MILLION)
  • TABLE 213. JAPAN SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DEVICE TYPE, 2018-2023 (USD MILLION)
  • TABLE 214. JAPAN SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DEVICE TYPE, 2024-2030 (USD MILLION)
  • TABLE 215. JAPAN SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY LABORATORY DEVICES, 2018-2023 (USD MILLION)
  • TABLE 216. JAPAN SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY LABORATORY DEVICES, 2024-2030 (USD MILLION)
  • TABLE 217. JAPAN SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY POINT OF CARE DEVICES, 2018-2023 (USD MILLION)
  • TABLE 218. JAPAN SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY POINT OF CARE DEVICES, 2024-2030 (USD MILLION)
  • TABLE 219. JAPAN SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 220. JAPAN SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 221. MALAYSIA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 222. MALAYSIA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 223. MALAYSIA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC METHODS, 2018-2023 (USD MILLION)
  • TABLE 224. MALAYSIA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC METHODS, 2024-2030 (USD MILLION)
  • TABLE 225. MALAYSIA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DEVICE TYPE, 2018-2023 (USD MILLION)
  • TABLE 226. MALAYSIA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DEVICE TYPE, 2024-2030 (USD MILLION)
  • TABLE 227. MALAYSIA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY LABORATORY DEVICES, 2018-2023 (USD MILLION)
  • TABLE 228. MALAYSIA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY LABORATORY DEVICES, 2024-2030 (USD MILLION)
  • TABLE 229. MALAYSIA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY POINT OF CARE DEVICES, 2018-2023 (USD MILLION)
  • TABLE 230. MALAYSIA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY POINT OF CARE DEVICES, 2024-2030 (USD MILLION)
  • TABLE 231. MALAYSIA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 232. MALAYSIA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 233. PHILIPPINES SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 234. PHILIPPINES SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 235. PHILIPPINES SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC METHODS, 2018-2023 (USD MILLION)
  • TABLE 236. PHILIPPINES SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC METHODS, 2024-2030 (USD MILLION)
  • TABLE 237. PHILIPPINES SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DEVICE TYPE, 2018-2023 (USD MILLION)
  • TABLE 238. PHILIPPINES SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DEVICE TYPE, 2024-2030 (USD MILLION)
  • TABLE 239. PHILIPPINES SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY LABORATORY DEVICES, 2018-2023 (USD MILLION)
  • TABLE 240. PHILIPPINES SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY LABORATORY DEVICES, 2024-2030 (USD MILLION)
  • TABLE 241. PHILIPPINES SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY POINT OF CARE DEVICES, 2018-2023 (USD MILLION)
  • TABLE 242. PHILIPPINES SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY POINT OF CARE DEVICES, 2024-2030 (USD MILLION)
  • TABLE 243. PHILIPPINES SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 244. PHILIPPINES SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 245. SINGAPORE SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 246. SINGAPORE SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 247. SINGAPORE SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC METHODS, 2018-2023 (USD MILLION)
  • TABLE 248. SINGAPORE SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC METHODS, 2024-2030 (USD MILLION)
  • TABLE 249. SINGAPORE SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DEVICE TYPE, 2018-2023 (USD MILLION)
  • TABLE 250. SINGAPORE SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DEVICE TYPE, 2024-2030 (USD MILLION)
  • TABLE 251. SINGAPORE SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY LABORATORY DEVICES, 2018-2023 (USD MILLION)
  • TABLE 252. SINGAPORE SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY LABORATORY DEVICES, 2024-2030 (USD MILLION)
  • TABLE 253. SINGAPORE SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY POINT OF CARE DEVICES, 2018-2023 (USD MILLION)
  • TABLE 254. SINGAPORE SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY POINT OF CARE DEVICES, 2024-2030 (USD MILLION)
  • TABLE 255. SINGAPORE SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 256. SINGAPORE SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 257. SOUTH KOREA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 258. SOUTH KOREA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 259. SOUTH KOREA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC METHODS, 2018-2023 (USD MILLION)
  • TABLE 260. SOUTH KOREA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC METHODS, 2024-2030 (USD MILLION)
  • TABLE 261. SOUTH KOREA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DEVICE TYPE, 2018-2023 (USD MILLION)
  • TABLE 262. SOUTH KOREA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DEVICE TYPE, 2024-2030 (USD MILLION)
  • TABLE 263. SOUTH KOREA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY LABORATORY DEVICES, 2018-2023 (USD MILLION)
  • TABLE 264. SOUTH KOREA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY LABORATORY DEVICES, 2024-2030 (USD MILLION)
  • TABLE 265. SOUTH KOREA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY POINT OF CARE DEVICES, 2018-2023 (USD MILLION)
  • TABLE 266. SOUTH KOREA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY POINT OF CARE DEVICES, 2024-2030 (USD MILLION)
  • TABLE 267. SOUTH KOREA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 268. SOUTH KOREA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 269. TAIWAN SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 270. TAIWAN SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 271. TAIWAN SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC METHODS, 2018-2023 (USD MILLION)
  • TABLE 272. TAIWAN SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC METHODS, 2024-2030 (USD MILLION)
  • TABLE 273. TAIWAN SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DEVICE TYPE, 2018-2023 (USD MILLION)
  • TABLE 274. TAIWAN SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DEVICE TYPE, 2024-2030 (USD MILLION)
  • TABLE 275. TAIWAN SEXUALLY